Kareena Kapoor's nutritionist shares 2 easy steps to eat non-vegetarian food: ‘Follow what your grandmother used to say'
Kareena Kapoor's nutritionist, Rujuta Diwekar, is known for sharing health tips related to the Indian diet on social media. In a post shared on June 27, she talked about the consumption of non-vegetarian foods like chicken, fish, meat, and more. According to Diwekar, the best way to eat these foods, which are often preferred for their high protein content, is to follow what our grandmothers used to advise us. If you are a non-vegetarian, keep these two important points in mind, suggested by Kareena Kapoor's nutritionist, Rujuta Diwekar. (Freepik)
Also Read | Nutritionist shares surprising probiotic, prebiotic foods in Indian kitchens apart from dahi: Tangy kanji to paneer
Sharing the post, Diwekar wrote, 'If you are a non-vegetarian, keep these two important points in mind.' She highlighted two important points to remember when eating non-vegetarian food. Let's find out what she said: 1. Non-veg dish should be part of the meal
According to the nutritionist, non-vegetarian food should always be a part of the main meal. 'It's not just about eating tangdi kebabs,' she stressed. Rather, she advised having chicken, fish or meat as a dish in a meal that consists of other things, too, including roti, rice, or bhakri. 2. Don't eat non-veg every single day
'The second thing your grandmother taught you is that you shouldn't eat non-vegetarian food every single day,' she advised. According to the nutritionist, Indians often stop themselves from eating non-vegetarian food on specific days by saying, 'Today is my Mangalwar (Tuesday), today is my Shukrawar (Friday).' She explained that if you have days when you eat non-veg and some days when you don't, then it is an ecologically safe way to consume meat.
Diwekar also highlighted a trend followed by people in the United States. She said, 'There is currently a big trend in the US called #MeatlessMonday. On Mondays, people don't eat meat because it's good. If we eat meat every day, we won't get the full benefits of it. But we should eat it a few days a week and avoid it on some days.'
'So, non-vegetarians don't need to become vegetarians to become healthier, and in the same way, vegetarians don't need to become non-vegetarians to become healthier,' she concluded.
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
2 hours ago
- India Today
Dr Ambrish Mithal decodes benefits of new weight-loss drugs
Dr Ambrish Mithal decodes benefits of new weight-loss drugs Jun27,2025 Credit: India Today Most type 2 diabetes patients are overweight, need to lose weight, and losing weight will help them even reverse or at least treat their diabetes better. Reverses diabetes Dr. Mithal describes body fat distribution in India is more on the belly. This, he says leads to a BMI lower than 30. However, the drugs can be used for someone whose BMI 27 and lower with comorbidities. Skinny fat Indians Dr. Mithal says that GLP-1 drugs are not magic but are powerful when taken along with proper diet high in protein and strength training. Credit: Getty Images GLP-1 drugs are not magic Rapid weight loss, especially without strength training, can lead to muscle loss. Therefore, while taking the medicines, ensure you exercise and have a proper diet to avoid severe muscle loss. Does it lead to muscle loss? The medicines have shown to slow the progression of Alzheimer's disease, and even reverse fatty liver. Happy side-effects GLP-1 drugs can help improved infertility in women with PCOS. Beyond weight loss Weight-loss drugs are not for everyone. Dr. Mithal says that assessing various factors like obesity and diabetes are required before prescribing the medicines. Not for everyone 'You can't eradicate obesity by using these drugs you have to eradicate obesity by preventing it," Dr. Mithal says. Forever drugs? For years, metformin has been the standard first-line treatment for type 2 diabetes. But newer medications are rapidly changing that equation, says Dr. Ambrish Mithal in conversation with Sneha Mordani for India Today's Booked. Beyond Metformin
Time of India
3 hours ago
- Time of India
Sunscreen Isn't Seasonal—It's Essential for Year-Round Skin Health
Many people still see sunscreen as a summer-only staple, reserved for beach days or tropical vacations. But the truth is, UV rays are present all year, regardless of season or weather. UVA rays responsible for premature aging and skin cancer penetrate clouds, windows, and even car windshields. Up to 80% of UV radiation can pass through overcast skies, and reflective surfaces like snow, sand, and water can double your exposure. Damage from this invisible assault is cumulative, permanent, and often goes unnoticed until it's too late. Aniruddha Ghosh,Dermatologist, MD - Dermatology , Venereology & Leprosy, Ghosh Clinic, Kolkata Over 80% of our sun exposure is incidental, picked up during everyday tasks like walking to work, driving, or sitting near a window. Skin aging —wrinkles, pigmentation, loss of elasticity is driven more by UV damage than by time. And while melanin offers some natural protection, it doesn't make darker skin immune to UV-related damage or skin cancer. Jyoti Agarkar, Dermatologist, Glamore Clinic, Mumbai Skipping sunscreen in winter or on cloudy days allows invisible damage to accumulate. This can lead to not only cosmetic concerns but also serious health risks. In fact, most skin cancers are directly linked to preventable UV exposure. Kathakali Chatarjee, Dermatologist, MD - MD- Skin & VD, Kolkata Sunscreen isn't just a beauty product; it's a basic health habit—akin to brushing your teeth or wearing a seatbelt. Daily SPF use helps protect your skin's appearance and integrity, supports long-term skin health, and reduces cancer risk. Nidhi Jindal, Dermatologist, MBBS, MD - Dermatology, Oliva Skin & Hair Clinic, Kolkata Ultimately, using sunscreen daily isn't just skincare—it's self-care. It's a small daily step toward protecting your future self. By making it a habit, you help halt the damage that accumulates silently from UV exposure over time. So whether it's sunny, cloudy, or cold, remember: sunscreen is not seasonal. It's essential. Sandip Lathiya, Dermatologist, MD - Dermatology , Venereology & Leprosy, Dr. Lathiya'S Skin Hair & Laser clinic, Bhavnagar, Gujarat The HALT THE DAMAGE, FACE THE WORLD campaign by LUPIN addresses the growing threat of sun damage among the Indian population. With rising UV exposure and rising pollution levels, contributing to Skin Damage by causing issues such as Pigmentation, Breakouts, and Premature aging. The campaign urges early education on the importance of Daily Sun Protection, and Proactive Skincare to Halt the Skin Damage, by promoting awareness and encouraging consistent use of dermatologist-backed solutions, this initiative empowers individuals to take control of their skin health before the damage becomes permanent. It's a vital step toward building a sun-smart generation that faces the world with confidence and care. Disclaimer - The above content is non-editorial, and ET Healthworld hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Genomic testing sees sharp uptake in India, now growing beyond metros
With 18 per cent CAGR, India's genomic diagnostics market is expanding into Tier 2 and 3 cities as affordability, cancer screening, and personalised care fuel adoption Anjali Singh Mumbai Demand for genomic testing in India has surged significantly over the past two to three years, fuelled by growing clinical awareness, rapid technological advancements and the rising adoption of personalised medicine. From being a niche service concentrated in major metros, genomic diagnostics are now expanding into Tier 2 and Tier 3 cities, reshaping the landscape of preventive and precision healthcare. The Indian genomic diagnostics market is valued at $550 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 18 per cent, reaching $2,066.31 million by 2030, according to industry estimates. Key drivers include wider physician adoption, declining test prices, improved accessibility and a shift in consumer behaviour towards proactive and personalised healthcare. Diagnostic majors such as Agilus Diagnostics, Metropolis Healthcare, Dr Lal PathLabs, Mahajan Imaging and Labs, and Redcliffe Labs report double-digit growth in the segment. While metros like Mumbai, Bengaluru and Delhi still contribute the lion's share, growing awareness and infrastructure in cities like Lucknow, Bhubaneswar, Pune, Kochi and Surat are driving demand beyond urban hubs. Test affordability has improved substantially. Prices for routine genomic tests—like BRCA1/2 (used to analyse a person's DNA to identify mutations in genes that increase the risk of breast and ovarian cancer) and NIPT (non-invasive prenatal testing, a blood test performed on pregnant women to assess the risk of certain genetic conditions in the foetus)—have come down by 30–40 per cent, now ranging between Rs 5,000 and Rs 20,000, depending on complexity. While advanced oncology panels and exome sequencing can still cost up to Rs 2 lakh, widespread adoption of high-throughput platforms and in-house test development has made even complex testing more accessible. Experts believe that although demand for genomic testing is rising across multiple segments, increasing cancer incidence and a countrywide focus on cancer detection and reproductive health have been key growth drivers. 'The rapid increase in demand for cancer tests, along with paediatric and reproductive health applications like prenatal testing and carrier testing, are major contributing factors driving growth in genetic testing. The country is also witnessing a rise in testing for rare genetic diseases, driven by India's huge genetic diversity,' said Nilaya Varma, group chief executive officer and co-founder, Primus Partners. 'Genomic testing now contributes 5–7 per cent of our total diagnostics revenue, up from under 2 per cent three years ago,' said Anand K, managing director and chief executive officer, Agilus Diagnostics. Redcliffe Labs pegs this number even higher, at 30–40 per cent, with consistent 20 per cent year-on-year growth in test volumes. 'We've seen a dramatic rise in genomic testing demand over the past five years, especially in oncology, rare diseases and reproductive health. What's encouraging is that Tier 2 and 3 cities like Lucknow, Bhubaneswar and Coimbatore are now actively adopting these tests,' said Himani Pandey, lab head – genomics, Redcliffe Labs. Metropolis Healthcare, which entered the genomics space three years ago, has seen over 50 per cent revenue growth in the segment and plans further expansion through investments in bioinformatics and next-generation sequencing (NGS) platforms. 'We've seen over 50 per cent revenue growth in genomics since our entry into the space three years ago. Genomic testing is increasingly being integrated into routine health check-ups, cancer diagnostics, rare disease screening and personalised treatment planning. We are investing heavily in bioinformatics and NGS platforms to scale further,' said Kirti Chadha, chief scientific and innovation officer, Metropolis Healthcare. Similarly, Dr Lal PathLabs, through its genomics division Genevolve, has launched over 500 tests covering oncogenomics, neurogenomics, rare disease panels and reproductive health. 'With Illumina's NovaSeq X platform at our national reference lab and a focused genomics sales team, we're bringing cutting-edge testing to both metros and smaller towns,' said Shankha Banerjee, chief executive officer, Dr Lal PathLabs. While margins on genomic tests can vary—and in many cases remain lower than routine diagnostics due to high input costs and low volumes—players see genomics as a long-term strategic bet. 'It's not just about margins—it's about clinical value and helping doctors make better treatment decisions,' said Shelly Mahajan, lab director at Mahajan Imaging. A common thread across players is the push for in-house development and Indian population–specific panels, often coupled with global partnerships for specialised tests. Most labs are also investing in AI-driven bioinformatics, advanced molecular labs and automation to enhance scalability. Yet, challenges remain. Despite cost reductions, insurance coverage for genomic tests in India is still extremely limited, creating affordability barriers for patients in lower-income segments. Industry leaders stress that broader insurance inclusion could accelerate adoption, particularly for cancer, rare diseases and reproductive health-related tests. Nonetheless, the momentum is clear: Genomic testing is no longer a fringe offering. With its ability to provide deep molecular insights for early diagnosis, targeted therapy and risk prediction, it is fast becoming a core pillar in India's diagnostics growth strategy.
